FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024291302> ?p ?o ?g. }

• W2024291302 endingPage "S112" @default.
• W2024291302 startingPage "S107" @default.
• W2024291302 abstract "In this phase III trial, 770 patients with clinical stage I-II Hodgkin's disease (HD) have been enrolled since November 1988. Preliminary results are given for the 605 (79%) patients who have completed their initial therapy. Patients were grouped according to 6 pretreatment prognostic characteristics. In the very favourable (VF) group, treatment consisted of mantle field alone. In the favourable (F) group, patients were randomized to either subtotal nodal irradiation (STNI), or 6 cycles of EBVP (epirubicin, bleomycin, vinblastine, prednisone) followed by involved-field irradiation (IF-RT). Unfavourable (U) patients were randomized to either 6 cycles of EBVP plus IF-RT, or to 6 cycles of MOPP/ABV hybrid plus IF-RT. Of the 35 VF patients, none have progressed during radiotherapy. Four patients relapsed and were salvaged. Three-year failure-free survival (FFS) was 82%; overall survival (OS) was 100%. Of the 254 F patients, 130 were treated with STNI and 124 with EBVP plus IF-RT. At 3 years, FFS rates were 81% (1 progression, 14 relapses) and 79% (5 progressions, 8 relapses), respectively. Corresponding OS rates were 99% and 100%. Of the 316 U patients, 160 received EBVP and 156 MOPP/ABV. At 3 years, FFS rates were 72% (18 progressions, 20 relapses) and 88% (7 progressions, 6 relapses), respectively (p < 0.001). Although OS rates were identical (92%), the entry in the U-EBVP arm was stopped in November 1992. We conclude that a treatment strategy based on prognostic factors allows the use of less aggressive treatment in favourable patients.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
• W2024291302 created "2016-06-24" @default.
• W2024291302 creator A5011615789 @default.
• W2024291302 creator A5022515988 @default.
• W2024291302 creator A5023992858 @default.
• W2024291302 creator A5038699632 @default.
• W2024291302 creator A5045092774 @default.
• W2024291302 creator A5060203039 @default.
• W2024291302 creator A5070508738 @default.
• W2024291302 creator A5077729501 @default.
• W2024291302 creator A5081216142 @default.
• W2024291302 creator A5087103462 @default.
• W2024291302 creator A5052386140 @default.
• W2024291302 date "1994-01-01" @default.
• W2024291302 modified "2023-09-27" @default.
• W2024291302 title "Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease" @default.
• W2024291302 cites W1536128075 @default.
• W2024291302 cites W1979222997 @default.
• W2024291302 cites W1985482535 @default.
• W2024291302 cites W2021699851 @default.
• W2024291302 cites W2027503751 @default.
• W2024291302 cites W2051536310 @default.
• W2024291302 cites W2063870002 @default.
• W2024291302 cites W2067324096 @default.
• W2024291302 cites W2093365696 @default.
• W2024291302 cites W2156906636 @default.
• W2024291302 cites W2248977291 @default.
• W2024291302 cites W2254858347 @default.
• W2024291302 cites W2322312023 @default.
• W2024291302 cites W2338057729 @default.
• W2024291302 cites W2411913910 @default.
• W2024291302 cites W2440561267 @default.
• W2024291302 doi "https://doi.org/10.1093/annonc/5.suppl_2.s107" @default.
• W2024291302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7515643" @default.
• W2024291302 hasPublicationYear "1994" @default.
• W2024291302 type Work @default.
• W2024291302 sameAs 2024291302 @default.
• W2024291302 citedByCount "74" @default.
• W2024291302 countsByYear W20242913022012 @default.
• W2024291302 countsByYear W20242913022013 @default.
• W2024291302 countsByYear W20242913022014 @default.
• W2024291302 countsByYear W20242913022015 @default.
• W2024291302 countsByYear W20242913022016 @default.
• W2024291302 countsByYear W20242913022022 @default.
• W2024291302 crossrefType "journal-article" @default.
• W2024291302 hasAuthorship W2024291302A5011615789 @default.
• W2024291302 hasAuthorship W2024291302A5022515988 @default.
• W2024291302 hasAuthorship W2024291302A5023992858 @default.
• W2024291302 hasAuthorship W2024291302A5038699632 @default.
• W2024291302 hasAuthorship W2024291302A5045092774 @default.
• W2024291302 hasAuthorship W2024291302A5052386140 @default.
• W2024291302 hasAuthorship W2024291302A5060203039 @default.
• W2024291302 hasAuthorship W2024291302A5070508738 @default.
• W2024291302 hasAuthorship W2024291302A5077729501 @default.
• W2024291302 hasAuthorship W2024291302A5081216142 @default.
• W2024291302 hasAuthorship W2024291302A5087103462 @default.
• W2024291302 hasBestOaLocation W20242913021 @default.
• W2024291302 hasConcept C126322002 @default.
• W2024291302 hasConcept C141071460 @default.
• W2024291302 hasConcept C146357865 @default.
• W2024291302 hasConcept C151730666 @default.
• W2024291302 hasConcept C168563851 @default.
• W2024291302 hasConcept C2776232574 @default.
• W2024291302 hasConcept C2776694085 @default.
• W2024291302 hasConcept C2776755627 @default.
• W2024291302 hasConcept C2777132456 @default.
• W2024291302 hasConcept C2778720950 @default.
• W2024291302 hasConcept C2779429289 @default.
• W2024291302 hasConcept C2780835546 @default.
• W2024291302 hasConcept C509974204 @default.
• W2024291302 hasConcept C71924100 @default.
• W2024291302 hasConcept C86803240 @default.
• W2024291302 hasConcept C90924648 @default.
• W2024291302 hasConceptScore W2024291302C126322002 @default.
• W2024291302 hasConceptScore W2024291302C141071460 @default.
• W2024291302 hasConceptScore W2024291302C146357865 @default.
• W2024291302 hasConceptScore W2024291302C151730666 @default.
• W2024291302 hasConceptScore W2024291302C168563851 @default.
• W2024291302 hasConceptScore W2024291302C2776232574 @default.
• W2024291302 hasConceptScore W2024291302C2776694085 @default.
• W2024291302 hasConceptScore W2024291302C2776755627 @default.
• W2024291302 hasConceptScore W2024291302C2777132456 @default.
• W2024291302 hasConceptScore W2024291302C2778720950 @default.
• W2024291302 hasConceptScore W2024291302C2779429289 @default.
• W2024291302 hasConceptScore W2024291302C2780835546 @default.
• W2024291302 hasConceptScore W2024291302C509974204 @default.
• W2024291302 hasConceptScore W2024291302C71924100 @default.
• W2024291302 hasConceptScore W2024291302C86803240 @default.
• W2024291302 hasConceptScore W2024291302C90924648 @default.
• W2024291302 hasLocation W20242913021 @default.
• W2024291302 hasLocation W20242913022 @default.
• W2024291302 hasOpenAccess W2024291302 @default.
• W2024291302 hasPrimaryLocation W20242913021 @default.
• W2024291302 hasRelatedWork W2077424156 @default.
• W2024291302 hasRelatedWork W2088178968 @default.
• W2024291302 hasRelatedWork W2101866183 @default.
• W2024291302 hasRelatedWork W2155856538 @default.
• W2024291302 hasRelatedWork W2163567381 @default.

• next